KRYS - クリスタル・バイオテック (Krystal Biotech Inc.) クリスタル・バイオテック

 KRYSのチャート


 KRYSの企業情報

symbol KRYS
会社名 Krystal Biotech Inc (クリスタル・バイオテック)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Krystal Biotech Inc. is a gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform or STAR-D platform that consists of a patent pending engineered viral vector based on herpes simplex virus 1 or HSV-1 and skin-optimized gene transfer technology to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Company''s KB103 is in preclinical development to treat dystrophic epidermolysis bullosa or DEB a rare and severe genetic disease. The Company''s KB104 is to treat Netherton Syndrome a severe form of ichthyosis which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation itchiness and dehydration.   クリスタル・バイオテックは米国のバイオ医薬品企業。主に皮膚疾患に対する遺伝子治療の開発・商業化に従事する。同社はHSV-1に基づくウィルスベクタ―と皮膚最適化遺伝子導入技術プラットフォ―ム「STAR-D」を開発。重度の遺伝病であるジストロフィ―性表皮水疱症に対する遺伝子治療「KB-103」を開発する。本社所在地はペンシルベニア州ピッツバ―グ。   Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.
本社所在地 2100 Wharton Street Suite 701 Pittsburgh PA 15203 USA
代表者氏名
代表者役職名
電話番号 +1 412-586-5830
設立年月日 42339
市場名 NASDAQ Small Cap
ipoyear 2017年
従業員数
url www.krystalbio.com
nasdaq_url https://www.nasdaq.com/symbol/krys
adr_tso
EBITDA EBITDA(百万ドル) -8.25600
終値(lastsale) 15.51
時価総額(marketcap) 170282987.16
時価総額 時価総額(百万ドル) 234.93030
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 189.48030
当期純利益 当期純利益(百万ドル) -11.09200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Krystal Biotech Inc revenues was not reported. Net loss increased from $1.3M to $4.4M. Higher net loss reflects Research and Development - Balancing increase from $698K to $2.9M (expense) General and Administrative - Balancing increase from $347K to $1.6M (expense) Stock-based Compensation in R&D increase of 82% to $122K (expense).

 KRYSのテクニカル分析


 KRYSのニュース

   Krystal Biotech''s KB105 Shows Detectable, Functionally Active TGM-1 Enzyme In Genetic Skin Condition  2021/07/02 11:43:19 Benzinga
Krystal Biotech Inc (NASDAQ: KRYS ) announced updated results from the Phase 1/2 trial evaluating topical administration of KB105 in patients with autosomal recessive congenital ichthyosis (ARCI) associated with mutations in the TGM1 gene. Data showed that repeat doses of KB105 were well-tolerated with no adverse events and no evidence Full story available on Benzinga.com
   H.C. Wainwright Stick to Their Buy Rating for Krystal Biotech Inc By Investing.com  2021/07/02 10:25:17 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Krystal Biotech Inc
   Krystal Biotech posts updated results from early-stage KB105 study  2021/07/01 20:25:26 Seeking Alpha
   Krystal Biotech to Participate in Upcoming Investor Conferences - June 03, 2021  2021/06/03 00:00:00 BioSpace
Krystal Biotech Inc., the leader in redosable gene therapies for rare diseases, announced participation in two upcoming virtual investor conferences.
   Soleus Capital Management, L.P. Buys Theratechnologies Inc, Krystal Biotech Inc, IVERIC bio ...  2021/05/18 18:38:32 GuruFocus
Related Stocks: KRYS , ISEE , AZN , VSPR , LNTH , IRMD , THTX , PCVX , ASMB , MDXG , F ,
   Krystal Biotech''s KB105 Shows Detectable, Functionally Active TGM-1 Enzyme In Genetic Skin Condition  2021/07/02 11:43:19 Benzinga
Krystal Biotech Inc (NASDAQ: KRYS ) announced updated results from the Phase 1/2 trial evaluating topical administration of KB105 in patients with autosomal recessive congenital ichthyosis (ARCI) associated with mutations in the TGM1 gene. Data showed that repeat doses of KB105 were well-tolerated with no adverse events and no evidence Full story available on Benzinga.com
   H.C. Wainwright Stick to Their Buy Rating for Krystal Biotech Inc By Investing.com  2021/07/02 10:25:17 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Krystal Biotech Inc
   Krystal Biotech posts updated results from early-stage KB105 study  2021/07/01 20:25:26 Seeking Alpha
   Krystal Biotech to Participate in Upcoming Investor Conferences - June 03, 2021  2021/06/03 00:00:00 BioSpace
Krystal Biotech Inc., the leader in redosable gene therapies for rare diseases, announced participation in two upcoming virtual investor conferences.
   Soleus Capital Management, L.P. Buys Theratechnologies Inc, Krystal Biotech Inc, IVERIC bio ...  2021/05/18 18:38:32 GuruFocus
Related Stocks: KRYS , ISEE , AZN , VSPR , LNTH , IRMD , THTX , PCVX , ASMB , MDXG , F ,

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クリスタル・バイオテック KRYS Krystal Biotech Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)